FDMT Company Profile and Key Details

Q: Who are the executives of FDMT?

Dr. An Song Ph.D.Chief Devel. OfficerMs. Theresa JankeCo-Founder & Chief of StaffDr. David H. Kirn M.D.Co-Founder, Chief Executive Officer & DirectorDr. Robert S. FishmanChief Medical Officer & Therapeutic Area Head of PulmonologyMr. August J. Moretti Esq., J.D.Chief Financial OfficerDr. Fred Kamal Ph.D.Pres & Chief Operating OfficerDr. Raphael Schiffmann M.D.Senior Vice President & Therapeutic Area Head of CardiologyDr. Robert Y. Kim M.B.A., M.D.Chief Medical OfficerDr. Fariborz Kamal Ph.D.Pres & Chief Operating OfficerDr. John F. Milligan Ph.D.Executive ChairmanMike ZanoniVice President of Investor RelationsDr. Scott P. Bizily J.D., Ph.D.Chief Legal & HR Officer and Corporation Sec.Ms. Karen S. CarothersController

NASDAQ : FDMT

4D Molecular Therapeutics

$10.40

-0.395-3.66%

Open: 12:49 PM

60.74

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

4D Molecular Therapeutics, Inc. (FDMT) stock declined over -3.66%, trading at $10.40 on NASDAQ, down from the previous close of $10.79. The stock opened at $10.77, fluctuating between $10.37 and $10.86 in the recent session.

Stock Snapshot

10.79

Prev. Close

543.4M

Market Cap

10.37

Day Low

-4.04

P/E Ratio

-2.57

EPS (TTM)

Cash Flow per Share

10.77

Open

52.27M

Number of Shares

10.86

Day High

91.26%

Free Float in %

0.01

Book Value

163.62K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 11, 2026	10.25	11.21	10.20	10.79	1.02M
May 08, 2026	9.08	10.15	9.06	10.14	628.03K
May 07, 2026	10.39	10.39	9.80	9.93	737.12K
May 06, 2026	9.76	10.43	9.65	10.42	711K
May 05, 2026	9.55	9.86	9.49	9.71	541.6K
May 04, 2026	9.10	9.55	9.10	9.44	548.7K
Apr 30, 2026	8.80	9.07	8.64	8.87	732.79K
Apr 29, 2026	9.51	9.51	8.72	8.81	849.89K
Apr 28, 2026	9.40	9.66	9.36	9.42	437.13K
Apr 27, 2026	9.27	9.77	9.27	9.45	630.32K
Apr 23, 2026	9.81	9.87	9.48	9.61	535.17K
Apr 22, 2026	9.85	9.96	9.69	9.80	685.42K
Apr 21, 2026	9.89	10.09	9.67	9.76	843.19K
Apr 20, 2026	10.27	10.59	10.01	10.07	473.08K
Apr 17, 2026	10.48	10.74	10.20	10.49	894.93K
Apr 16, 2026	9.75	10.10	9.53	10.06	836.57K
Apr 14, 2026	10.06	10.17	9.60	9.66	1.05M
Apr 13, 2026	9.82	10.23	9.82	10.04	553.13K
Apr 10, 2026	9.82	9.94	9.49	9.81	892.35K
Apr 09, 2026	10.00	10.02	9.70	9.84	389.09K

Contact Details

EmeryVille, CA 94608

United States

https://www.4dmoleculartherapeutics.com 510 505 2680

About Company

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Stock Peers

ARGX

31.11+3.98%

argenx SE$813.28 REGN

-2.12-0.30%

Regeneron Pharmaceuticals, Inc.$712.77 UTHR

4.94+0.87%

United Therapeutics Corporation$569.88 MDGL

-13.01-2.55%

Madrigal Pharmaceuticals, Inc.$497.03 VRTX

5.35+1.24%

Vertex Pharmaceuticals Incorporated$435.17 PRAX

1.79+0.54%

Praxis Precision Medicines, Inc.$331.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

7.17+2.35%

Krystal Biotech, Inc.$312.88 ALNY

-10.21-3.46%

Alnylam Pharmaceuticals, Inc.$284.84 ASND

0.010.00%

Ascendis Pharma A/S$238.67

Company Overview

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) closed at $10.39 USD, losing -$0.39 (-3.66%) from the previous close of $10.79. The stock is currently mid-range between its 52-week high and low $3.02 and $12.34. With a market capitalization of about $543.40 million, 4D Molecular Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.76). Key stats such as the average daily volume over the past year has been around 755.75 thousand shares, volume is running light vs its 52-week average. Headquartered in EmeryVille, CA, 4D Molecular Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David H. Kirn, the company employs approximately 227 people and listed since December 11, 2020. 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.

Technical Performance

FDMT has shown mixed momentum, gaining 1.6% over the past week and -22.56% over the past quarter, though year-to-date performance is up 1.6%. Short-term trend indicators are bearishly aligned (SMA20 4.18%, SMA50 12.32%, SMA200 29.79%). The stock’s 14-day RSI is 57.59 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.72% below its high and over 332.21% above its low. Average 10-day trading volume of 697.83 thousand shares is in line with the 3-month average of 728.67 thousand, indicating normal recent market interest.

Valuation Metrics

4D Molecular Therapeutics, Inc. trades at a P/E ratio of -4.49, slightly below the S&P 500 average, with a price-to-sales ratio of 6.29 and a price-to-book ratio of 1.6 suggesting the stock is closer to book value. The P/FCF stands at -4.26, also above market averages.

Dividend & Fair Value

4D Molecular Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.67. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

4D Molecular Therapeutics, Inc. generated EPS of -$3.94 over the past year. Five-year average earnings growth is -9.89%. Wall Street analysts project EPS growth of -6.34% annually over the next five years. The latest quarter delivered EPS of -$1.01. The next quarter is forecast at -$0.53. Next year's EPS is expected at -$15.08. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $38.00 to $21.00. The high target offers 252.18% upside. The low target suggests 94.62% downside. The mean target is $29.07. This offers 169.42% upside. 4D Molecular Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 4.12%. The prior quarter beat by -181.13%. Over the last six quarters, Apple has recorded several small beats. These include 12.5% in February 28, 2025.

Shareholding & Insider Activity

4D Molecular Therapeutics, Inc. has 46.70 million shares outstanding. The public float is 35.70 million shares, elevated short interest at 8.32% of float. This equals 3.70 million shares. The short ratio is 9.34 days. Institutional investors hold 91.37% of the float. Insiders own 3.85%. VIKING GLOBAL INVESTORS LP holds 4.25 million shares, YAO TONY DUNG LING has 1.06 million shares and Kirn David has 1.06 million shares. Over the past six months, insider transactions show net selling. They sold 3.89 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, 4D Molecular Therapeutics generated $20.72M in revenue, or $0.53 per share. Gross margin was 72.26%, operating margin -544.65%, and net profit margin -486.59%. Returns are negative, with ROA at -29.67% and ROE at -32.76%.
On valuation metrics, 4D Molecular Therapeutics trades at a P/E of -4.49, P/S of 6.29 and P/B of 1.60. The current ratio is 9.34 and quick ratio is 9.34. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -54.05 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -6.30.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, 4D Molecular Therapeutics posted revenue of $20.72M, down slightly from $3.13M in the prior quarter. Gross profit was $14.97M (margin 72.26%). Operating income was - $112.87M (margin -544.6%). Net income was- $100.84M (EPS - $2.58).
The company ended the quarter with $288.23M in cash and short-term investments, a total debt of $14.67M, and net debt of - $234.44M. Total assets were $339.89M, with equity of $307.83M. Financials further reflected weakness, with operating cash flow of - $75.79M, free cash flow of - $78.56M, and capital expenditures of - $2.77M.

Price Forecast & Outlook

Our AI price prediction model suggests that 4D Molecular Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.52%, with price expected at $10.41 by May 25, 2026, within a range of $9.89 to $10.94 3-Month Outlook: Projected rise of 57.83%, reaching $17.03 by August 07, 2026, with a range of $15.56 to $18.21. 1-Year Outlook: Projected gain of 133.09%, with price at $25.15 by May 11, 2027, within a range of $6.38 to $41.01.

Key Takeaways

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares are flat 1.6% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows 4D Molecular Therapeutics, Inc. trading at a premium to the broader market with a P/E of -4.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $32.61, suggesting 202.22% upside. Our AI forecast model points to short-term weakness (-3.52% over two weeks), a medium-term rise (57.83% over three months), and a longer-term gain (133.09% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current 4D Molecular Therapeutics, Inc. (FDMT) stock price?

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) stock price is $10.40 in the last trading session. During the trading session, FDMT stock reached the peak price of $10.86 while $10.37 was the lowest point it dropped to. The percentage change in FDMT stock occurred in the recent session was -3.66% while the dollar amount for the price change in FDMT stock was - $0.40.

FDMT's industry and sector of operation?

The NASDAQ listed FDMT is part of Biotechnology industry that operates in the broader Healthcare sector. 4D Molecular Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FDMT?

Dr. An Song Ph.D.
Chief Devel. Officer
Ms. Theresa Janke
Co-Founder & Chief of Staff
Dr. David H. Kirn M.D.
Co-Founder, Chief Executive Officer & Director
Dr. Robert S. Fishman
Chief Medical Officer & Therapeutic Area Head of Pulmonology
Mr. August J. Moretti Esq., J.D.
Chief Financial Officer
Dr. Fred Kamal Ph.D.
Pres & Chief Operating Officer
Dr. Raphael Schiffmann M.D.
Senior Vice President & Therapeutic Area Head of Cardiology
Dr. Robert Y. Kim M.B.A., M.D.
Chief Medical Officer
Dr. Fariborz Kamal Ph.D.
Pres & Chief Operating Officer
Dr. John F. Milligan Ph.D.
Executive Chairman
Mike Zanoni
Vice President of Investor Relations
Dr. Scott P. Bizily J.D., Ph.D.
Chief Legal & HR Officer and Corporation Sec.
Ms. Karen S. Carothers
Controller

How FDMT did perform over past 52-week?

FDMT's closing price is 257.29% higher than its 52-week low of $3.02 where as its distance from 52-week high of $12.34 is -12.56%.

How many employees does FDMT have?

Number of FDMT employees currently stands at 227.

Link for FDMT official website?

Official Website of FDMT is: https://www.4dmoleculartherapeutics.com

How do I contact FDMT?

FDMT could be contacted at phone 510 505 2680 and can also be accessed through its website. FDMT operates from 5858 Horton Street, EmeryVille, CA 94608, United States.

How many shares of FDMT are traded daily?

FDMT stock volume for the day was 163.62K shares. The average number of FDMT shares traded daily for last 3 months was 755.75K.

What is the market cap of FDMT currently?

The market value of FDMT currently stands at $543.40M with its latest stock price at $10.40 and 52.27M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	227
Beta	3.01
Sales or Revenue	$20.72M
5Y Sales Change%	-0.531%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FDMT Company Profile and Key Details

4D Molecular Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways